Global Perspective on Treatment of Hepatocellular Carcinoma

home / peer-exchange / hcc-treatment-global

Diagnosis of HCC: Presentation of Disease

EP. 1: Diagnosis of HCC: Presentation of Disease

Global Multidisciplinary Care in HCC

EP. 2: Global Multidisciplinary Care in HCC

Identifying Staging Systems for HCC

EP. 3: Identifying Staging Systems for HCC

HCC: The Criteria for Adjuvant Therapy

EP. 4: HCC: The Criteria for Adjuvant Therapy

Treating Hepatitis C in HCC

EP. 5: Treating Hepatitis C in HCC

Neoadjuvant and Local Therapy in HCC

EP. 6: Neoadjuvant and Local Therapy in HCC

Rationale for TACE in Locally Advanced HCC

EP. 7: Rationale for TACE in Locally Advanced HCC

HCC Treatment: Sorafenib + TACE

EP. 8: HCC Treatment: Sorafenib + TACE

Liver-Directed Therapy in HCC: Yttrium-90

EP. 9: Liver-Directed Therapy in HCC: Yttrium-90

Implication of Upfront Lenvatinib in HCC

EP. 10: Implication of Upfront Lenvatinib in HCC

HCC: Use of Lenvatinib and Sorafenib

EP. 11: HCC: Use of Lenvatinib and Sorafenib

Global Use of Regorafenib in HCC

EP. 12: Global Use of Regorafenib in HCC

Nivolumab and Checkpoint Inhibitors in HCC

EP. 13: Nivolumab and Checkpoint Inhibitors in HCC

Clinical Rationale for Cabozantinib in HCC

EP. 14: Clinical Rationale for Cabozantinib in HCC

Emerging Agents for Treatment of HCC

EP. 15: Emerging Agents for Treatment of HCC

Latest Conference Coverage

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis

Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma

Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.